An Open-Label Pilot Study of the Efficacy and Tolerability of Once-Daily Didanosine Versus Twice-Daily Didanosine

Didanosine is a nucleoside analogue that suppresses HIV viral replication. Pharmacokinetic studies have demonstrated decreased bioavailability of didanosine when it is administered once a day, prompting utilization of a twice-daily dosing regimen. However, the intracellular half-life of didanosine i...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 1998-08, Vol.27 (2), p.400-401
Main Authors: Keiser, Philip, Turner, Dianna, Ramilo, Octavio, Kvanli, Mary Beth, Smith, James W., Nassar, Naiel
Format: Article
Language:English
Subjects:
Adult
AIDS
AIDS/HIV
Anti-HIV Agents - administration & dosage
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretrovirals
Antiviral agents
Biological and medical sciences
Brief Reports
Clinical trials
Didanosine - administration & dosage
Dosage
Drug Administration Schedule
Hammers
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Male
Medical sciences
Pharmacology. Drug treatments
Pilot Projects
Viral Load
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Didanosine is a nucleoside analogue that suppresses HIV viral replication. Pharmacokinetic studies have demonstrated decreased bioavailability of didanosine when it is administered once a day, prompting utilization of a twice-daily dosing regimen. However, the intracellular half-life of didanosine is less than or equal to 24 hours; making it possible theoretically to suppress viral replication with once-daily dosing intervals. Once-daily dosing may improve drug tolerability, facilitating patient adherence to complex antiretroviral regimens that contain didanosine. Currently there are no data concerning the ability of this dosing regimen to suppress viral replication. To further evaluate the clinical utility of alternative dosing of didanosine, we performed a comparative trial to study the effects of once- and twice-daily didanosine dosing on viral load in HIV-infected patients.
ISSN:1058-4838
1537-6591
DOI:10.1086/517700